Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
A Study of LY2216684 and Digoxin in Healthy Subjects
The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684.
- Trial name
- NCT01266590
- Testing
- LY2216684, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression
This study will compare the effect of three transcranial photobiomodulation (t-PBM) doses (high, middle, and low irradiance) to sham t-PBM on PFC CBF as assessed with fMRI (BOLD) in this multi-center, phase I, double-blinded…
- Trial name
- TRIADE (NCT04366258)
- Testing
- Transcranial Photobiomodulator
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- aTBS (NCT03068715)
- Testing
- Active TBS-DLPFC, Open label TBS-DLPFC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Major Depressive Disorder
Brain Imaging Techniques That Predict Antidepressant Responsiveness
Do functional brain changes occur during Venlafaxine ER (extended release) versus Fluoxetine treatment and do changes in selective structures, such as the amygdala, predict treatment response?
- Trial name
- WyethKolden (NCT00909155)
- Testing
- Venlafaxine ERT, Fluoxetine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Major Depressive Disorder, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) and preferences of hemispheric…
- Trial name
- NCT00404755
- Testing
- escitalopram, bupropion, imipramine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Anhedonia
Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can increase goal-directed behavior in participants with major depressive disorder and elevated symptoms of anhedonia.
- Trial name
- DEBRA (NCT05084924)
- Testing
- Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Effects of Amygdala Neurofeedback on Depressive Symptoms
The purpose of this study is to determine the clinical efficacy of augmenting cognitive-behavioral therapy with real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) training to increase the amygdala's…
- Trial name
- NCT02709161
- Testing
- real-time fMRI neurofeedback: Amygdala, real-time fMRI neurofeedback: HIPS
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kymberly Young
Major Depressive Disorder
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder…
- Trial name
- NCT00985725
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 33 sites in United States
- Volunteers
- 143 people
- Sponsor
- Shire
Major Depressive Disorder
Safety of REL-1017 for Major Depressive Disorder
This was a 1-year, multicenter, open-label, long-term study to assess the safety of REL-1017 once daily (QD) as monotherapy or as adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-OLS (NCT04855760)
- Testing
- REL-1017
- Where
- 9 sites in United States
- Volunteers
- 627 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01197508
- Testing
- TC-5214
- Where
- 87 sites in Argentina, Brazil and 15 more
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Alcohol Abuse, Schizophrenia
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community…
- Conditions
- Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- CMETG (NCT01567943)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Major Depression, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
- Conditions
- Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
- Trial name
- NCT00296725
- Testing
- Fluoxetine, Imipramine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Late-life depression is characterized by both affective (mood) symptoms and cognitive deficits. There is currently no intervention that may provide consistent benefits to both mood and cognitive performance.
- Trial name
- NCT02816138
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University Medical Center
Depression, Postpartum
Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression
This study will evaluate the effectiveness of antidepressant medication alone and interpersonal psychotherapy alone in treating women with postpartum depression.
- Trial name
- NCT00602355
- Testing
- Sertraline, Interpersonal psychotherapy (IPT), Clinical management
- Where
- 2 sites in United States
- Volunteers
- 162 people
- Sponsor
- Women and Infants Hospital of Rhode Island